Eli Lilly Raises 2026 Sales Outlook on Strong Mounjaro, Zepbound Demand
Eli Lilly raised its full-year sales outlook after third-quarter results topped expectations. Revenue rose 38.6% year over year to $24.4 billion, beating consensus by $1.78 billion.
Story updates
03:13:46 PM UTC
SquawkNews
What happened? Shares of global pharmaceutical company Eli Lilly NYSE:LLYjumped 8.1% in the morning session after the company reported third-quarter 2026 non-GAAP earnings growth and raised the midpoint of its full-year revenue guidance by $5.5 billion.According to a company press release, Eli Lill…
Eli Lilly and Co. (LLY, Financials), the pharmaceutical company, raised its full-year sales outlook after third-quarter results topped expectations on strong demand for Mounjaro and Zepbound.Revenue rose 38.6% from a year earlier to $24.4 billion, beating consensus by $1.78 billion.Non-GAAP earning…